COVID
Vaccine Boosters Add Up to Billions for Drug Makers
September 27, 2021
Stock holder
reports for vaccine companies producing COVID-19 jabs should be full of
optimism and good news as booster requirements are implemented.
“Billions more
in profits are at stake for some vaccine makers as the U.S. moves toward
dispensing COVID-19 booster shots to shore up Americans’ protection against the
virus,” an AP investigation found.
Between the
continual worldwide rollout of first-time shots and the boosters, Pfizer and
Moderna are set to gain exponentially — and Wall Street is watching, the AP
said.
“Morningstar
analyst Karen Andersen expects boosters alone to bring in about $26 billion in
global sales next year for Pfizer and BioNTech and around $14 billion for
Moderna if they are endorsed for nearly all Americans,” the AP added. One
reason for the boost is that booster shots won’t have research and development
costs taking from the profits.
In other news,
the AP said Pfizer expects its COVID mRNA shot to generate $35.5 billion in
2021, more than five times its previous highest-selling shot for pneumococcal
disease.
SOURCE: AP News September 25, 2021
See also: Tennis Pro Says He
Regrets Getting Vaccinated, Has a ‘Series or Problems’
See also: Firefighters Say
They’re Seeing ‘Large Numbers’ of Vaccine Complications
